GL
HZNP

Governors Lane’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Governors Lane’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-342,500
Closed -$39.6M – 70
2023
Q3 		$39.6M Buy
342,500
+99,981
+41% +$10.7M 6.32% 1
2023
Q2 		$24.9M Sell
242,519
-209,281
-46% -$22.1M 3.43% 11
2023
Q1 		$49.3M Buy
451,800
+298,000
+194% +$32.9M 6.25% 2
2022
Q4 		$17.5M Buy
+153,800
New +$12.8M 1.8% 13

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Governors Lane's HZNP Position: Q4 2023 in Review

Governors Lane sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 342,500 shares — an estimated $39.6M sold.

Governors Lane first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $49.3M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Governors Lane reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Governors Lane sold 342,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $39.6M.
  • Governors Lane first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Governors Lane's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $49.3M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Governors Lane's 13F filing for Q4 2023, filed 14 Feb 2024.